Medications

Bronchial carcinoma: Added benefit of crizotinib not proven

Since August 2016 crizotinib (trade name: Xalkori) has also been available for adults with advanced non-small cell lung cancer (NSCLC) in whom the structure of the enzyme "proto-oncogene tyrosine-protein kinase" (ROS1) is ...

Medications

Crizotinib in bronchial carcinoma: New data not informative

Crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) with high activity of the enzyme anaplastic lymphoma kinase (ALK) who have already ...

Diseases, Conditions, Syndromes

Glaxo plant with Legionnaires' bacteria is quiet for second day

All was quiet Wednesday at a GlaxoSmithKline pharmaceutical plant that was shut down after the drug maker discovered the bacteria that cause potentially fatal Legionnaires' disease in a cooling tower at the site.

Diseases, Conditions, Syndromes

Drugmaker Glaxo shuts down plant over Legionnaires' bacteria

Drugmaker GlaxoSmithKline shut down a plant Tuesday that produces inhaled medications after discovering the bacteria that causes Legionnaire's disease, a potentially fatal form of pneumonia.

Oncology & Cancer

NICE says 'not enough data' to approve drug for ovarian cancer

The National Institute for Health and Care Excellence (NICE) says it cannot give a positive decision over whether to recommend a new drug for ovarian cancer unless its makers provide more information on cost. A final decision ...

page 8 from 20